Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,017 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
Gibson CM, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, Tricoci P, Alexander JH, Kastelein JJP, Mehran R, Bode C, Lewis BS, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo DJ, Duerschmied D, Ophuis TO, Merkely B. Gibson CM, et al. Among authors: duffy d. Am Heart J. 2019 Feb;208:81-90. doi: 10.1016/j.ahj.2018.11.008. Epub 2018 Nov 22. Am Heart J. 2019. PMID: 30580130 Clinical Trial.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, Nicholls SJ, Pocock S, Goodman SG, Alexander JH, Lincoff AM, Bode C, Duffy D, Heise M, Berman G, Mears SJ, Tricoci P, Deckelbaum LI, Steg PG, Ridker P, Mehran R. Gibson CM, et al. Among authors: duffy d. Am Heart J. 2021 Jan;231:121-127. doi: 10.1016/j.ahj.2020.10.052. Epub 2020 Oct 13. Am Heart J. 2021. PMID: 33065120 Free article.
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Kalayci A, Gibson CM, Ridker PM, Wright SD, Kingwell BA, Korjian S, Chi G, Lee JJ, Tricoci P, Kazmi SH, Fitzgerald C, Shaunik A, Berman G, Duffy D, Libby P. Kalayci A, et al. Among authors: duffy d. Curr Atheroscler Rep. 2022 Jul;24(7):585-597. doi: 10.1007/s11883-022-01025-7. Epub 2022 May 7. Curr Atheroscler Rep. 2022. PMID: 35524914 Free PMC article. Review.
Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.
Zheng B, Goto S, Clementi R, Feaster J, Duffy D, Dalitz P, Airey J, Korjian S, Tortorici MA, Roberts J, Gibson CM. Zheng B, et al. Among authors: duffy d. Clin Transl Sci. 2022 Oct;15(10):2331-2341. doi: 10.1111/cts.13361. Epub 2022 Aug 7. Clin Transl Sci. 2022. PMID: 35933730 Free PMC article. Clinical Trial.
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
Gibson CM, Kazmi SHA, Korjian S, Chi G, Phillips AT, Montazerin SM, Duffy D, Zheng B, Heise M, Liss C, Deckelbaum LI, Wright SD, Gille A. Gibson CM, et al. Among authors: duffy d. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221121507. doi: 10.1177/10742484221121507. J Cardiovasc Pharmacol Ther. 2022. PMID: 36282079 Free article. Clinical Trial.
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction.
Korjian S, Kazmi SHA, Chi G, Kalayci A, Lee JJ, Talib U, Wright SD, Duffy D, Kingwell BA, Mehran R, Ridker PM, Gibson CM. Korjian S, et al. Among authors: duffy d. Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):387-398. doi: 10.1093/ehjcvp/pvad014. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36787889 Free PMC article. Review.
1,017 results